Expression of somatostatin receptors, dopamine D 2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas

Endocrine-Related Cancer

Volumn 18, Issue 2, 2011, Pages 287-300

  Saveanu, Alexandru ^a,b   Muresan, Mihaela ^a,c   De Micco, Catherine ^d   Taieb, David ^d   Germanetti, Anne Laure ^b   Sebag, Frederic ^d   Henry, Jean François ^d   Brunaud, Laurent ^e   Enjalbert, Alain ^a,b   Weryha, Georges ^c   Barlier, Anne ^a,b  

^a HÔPITAL DE LA CONCEPTION   (France)

^b University of Mediterranée   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCURONIDASE; DOPAMINE 2 RECEPTOR; MESSENGER RNA; NORADRENALIN; SOMATOSTATIN RECEPTOR; VESICULAR MONOAMINE TRANSPORTER;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOPLASM VESICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PANCREATIC NEOPLASMS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; VESICULAR MONOAMINE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 79953173931     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-10-0175     Document Type: Article

References (71)

1. Amara SG, Sonders MS, Zahniser NR, Povlock SL & Daniels GM 1998 Molecular physiology and regulation of catecholamine transporters. Advances in Pharmacology 42 164-168. (doi:10.1016/S1054-3589(08)60718-8)
2. 123I- metaiodobenzylguanidine (MIBG), scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clinical Endocrinology 69 181-188. (doi:10.1111/j.1365-2265.2008.03256.x)
3. Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C & Kjaer A 2008 Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 87 223-232. (doi:10.1159/000113128)
4. Brown JM, Hanson GR & Fleckenstein AE 2001 Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. Journal of Pharmacology and Experimental Therapeutics 298 1150-1153. (Pubitemid 32761932)
5. de Bruin C, Feelders RA, Lamberts SW & Hofland LJ 2009 Somatostatin and dopamine receptors as targets for medical treatment of Cushing's syndrome. Reviews in Endocrine & Metabolic Disorders 10 91-102. (doi:10.1007/s11154- 008-9082-4)
6. Cleary S & Phillips JK 2006 The norepinephrine transporter and pheochromocytoma. Annals of the New York Academy of Sciences 1073 263-269. (doi:10.1196/annals.1353.029)
7. Cleary S, Brouwers FM, Eisenhofer G, Pacak K, Christie DL, Lipski J, McNeil AR & Phillips JK 2005 Expression of the noradrenaline transporter and phenylethanolamine N-methyltransferase in normal human adrenal gland and phaeochromocytoma. Cell Tissue Research 322 443-453. (doi:10.1007/s00441-005- 0026-y)
8. Duet M, Sauvaget E, Petelle B, Rizzo N, Guichard JP, Wassef M, Le Cloirec J, Herman P & Tran Ba Huy P 2003 Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. Journal of Nuclear Medicine 44 1767-1774. (Pubitemid 39663308)
9. Eisenhofer G, Huynh TT, Hiroi M & Pacak K 2001 Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma. Reviews in Endocrine & Metabolic Disorders 2 297-311. (doi:10.1023/A:1011572617314)
10. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR & Pacak K 2008 Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Hormone and Metabolic Research 40 329-337. (doi:10.1055/s-2008-1073156)
11. Epelbaum J, Bertherat J, Prevost G, Kordon C, Meyerhof W, Wulfsen I, Richter D & Plouin PF 1995 Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 80 1837-1844. (doi:10.1210/jc.80.6.1837)
12. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, Wolbers JG & Kwekkeboom DJ 2006 Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. Journal of Nuclear Medicine 47 1599-1606. (Pubitemid 47545024)
13. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW & van der Lely AJ 2009 Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 69 2207-2226. (doi:10.2165/11318510-000000000- 00000)
14. Florio T, Barbieri F, Spaziante R, Zona G, Hofland LJ, van Koetsveld PM, Feelders RA, Stalla GK, Theodoropoulou M, Culler MD et al. 2008 Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-Related Cancer 15 583-596. (doi:10.1677/ERC-07- 0271)
15. Forrer F, Riedweg I, Maecke HR & Mueller-Brand J 2008 Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging 52 334-340.
16. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R & Virgolini IJ 2007 68Ga-DOTA-Tyr3- octreotide PET, in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. Journal of Nuclear Medicine 48 508-518. (doi:10.2967/jnumed.106.035667)
17. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ & Turner FE 1993 Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. Journal of Nuclear Medicine 34 1140-1146. (Pubitemid 23191332)
18. Grant M, Alturaihi H, Jaquet P, Collier B & Kumar U 2008 Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Molecular Endocrinology 22 2278-2292. (doi:10.1210/me.2007-0334)
19. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP et al. 2001 [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 86 685-693. (doi:10.1210/jc.86.2.685)
20. Havekes B, King K, Lai EW, Romijn JA, Corssmit EP & Pacak K 2010 New imaging approaches to phaeochromocytomas and paragangliomas. Clinical Endocrinology 72 137-145. (doi:10.1111/j.1365-2265.2009.03648.x)
21. de Herder WW & Hofland LJ 2004 Somatostatin receptors in pheochromocytoma. Frontiers of Hormone Research 31 145-154. (doi:10.1159/ 000074662)
22. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G et al. 2004 A single-dose comparison of the acute effects between the newsomatostatin analog SOM230 and octreotide in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 89 638-645. (doi:10.1210/jc.2003-031052)
23. Hofland LJ, Liu Q, Van Koetsveld PM, Zuijderwijk J, Van Der Ham F, De Krijger RR, Schonbrunn A & Lamberts SW 1999 Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. Journal of Clinical Endocrinology and Metabolism 84 775-780. (doi:10.1210/jc.84.2.775)
24. Huynh TT, Pacak K, Brouwers FM, Abu-Asab MS, Worrell RA, Walther MM, Elkahloun AG, Goldstein DS, Cleary S & Eisenhofer G 2005 Different expression of catecholamine transporters in phaeochromocytomas frompatientswith von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. European Journal of Endocrinology 153 551-563. (doi:10.1530/eje.1.01987)
25. Ilias I & Pacak K 2008 A clinical overview of pheochromocytomas/ paragangliomas and carcinoid tumors. Nuclear Medicine and Biology 35 27-34. (doi:10.1016/j.nucmedbio.2008.04.007)
26. 123I-metaiodobenzylguanidine and 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. Journal of Nuclear Medicine 49 1613-1619. (doi:10.2967/jnumed.108.052373)
27. Invitti C, De Martin I, Bolla GB, Pecori Giraldi F, Maestri E, Leonetti G & Cavagnini F 1993 Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors. Hormone Research 40 156-160. (doi:10.1159/000183786)
28. Izumi Y, Yamamoto N, Kume T, Katsuki H, Sawada H & Akaike A 2008 Regulation of intracellular dopamine levels by dopaminergic drugs: involvement of vesicular monoamine transporter. European Journal of Pharmacology 582 52-61. (doi:10.1016/j.ejphar.2007.12.015)
29. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A & Culler MD 2005 Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. European Journal of Endocrinology 153 135-141. (doi:10.1530/eje.1.01950)
30. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R et al. 2001 Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. Journal of Clinical Endocrinology and Metabolism 86 895-902. (doi:10.1210/jc.86.2.895)
31. Kimura N, Pilichowska M, Date F, Kimura I & Schindler M 1999 Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clinical Cancer Research 5 3483-3487.
32. Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H, Forssell-Aronsson E & Nilsson O 2003 Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. British Journal of Cancer 89 1383-1388. (doi:10.1038/sj.bjc.6601276)
33. Kolby L, Bernhardt P, Johanson V, Wangberg B, Muth A, Jansson S, Forssell-Aronsson E, Nilsson O & Ahlman H 2006 Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Annals of the New York Academy of Sciences 1073 491-497. (doi:10.1196/annals.1353.051)
34. 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. Journal of Nuclear Medicine 49 1232-1237. (doi:10.2967/jnumed.107.047738)
35. Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, Hensen J & Lehnert H 1997 Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clinical Endocrinology 46 39-44. (doi:10.1046/j.1365-2265.1997.d01-1738.x)
36. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S & Seino Y 1994 Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. Journal of Clinical Investigation 93 1321-1325. (doi:10.1172/JCI117090)
37. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW & Krenning EP 2010 Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer 17 R53-R73. (doi:10.1677/ERC-09-0078)
38. Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, Baudin E, Luton JP & Plouin PF 2002 Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clinical Endocrinology 57 629-634. (doi:10.1046/j.1365-2265.2002.01658.x)
39. 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. British Journal of Cancer 70 97-101. (doi:10.1038/bjc.1994.256)
40. Mannelli M, Pupilli C, Fabbri G, Musante R, De Feo ML, Franchi F & Giusti G 1988 Endogenous dopamine (DA) and DA2 receptors: a mechanism limiting excessive sympathetic-adrenal discharge in humans. Journal of Clinical Endocrinology and Metabolism 66 626-631. (doi:10.1210/jcem-66-3-626)
41. Martiniova L, Ohta S, Guion P, Schimel D, Lai EW, Klaunberg B, Jagoda E & Pacak K 2006 Anatomical and functional imaging of tumors in animal models: focus on pheochromocytoma. Annals of the New York Academy of Sciences 1073 392-404. (doi:10.1196/annals.1353.043)
42. Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R &Lehnert H 2003 Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. Journal of Clinical Endocrinology and Metabolism 88 5150-5157. (doi:10.1210/jc.2003-030262)
43. Oberg K, Ferone D, Kaltsas G, Knigge UP, Taal B & Plockinger U 2009 ENETS consensus guidelines for the standards of care in neuroendocrine tumors: biotherapy. Neuroendocrinology 90 209-213. (doi:10.1159/000183751)
44. O'Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, Ruszniewski P & Barlier A 2006 The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. European Journal of Endocrinology 155 849-857. (doi:10.1530/eje.1.02307)
45. Pasquali D, Rossi V, Conzo G, Pannone G, Bufo P, De Bellis A, Renzullo A, Bellastella G, Colao A, Vallone G et al. 2008 Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. Journal of Molecular Endocrinology 40 263-271. (doi:10.1677/JME-08-0012)
46. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ et al. 2010 Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 95 2781-2789. (doi:10.1210/jc.2009-2272)
47. Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, van Koetsveld PM, Barreca A, De Caro ML, Lombardi G et al. 2004 Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. Journal of Clinical Endocrinology and Metabolism 89 4493-4502. (doi:10.1210/jc.2003-031746)
48. Plouin PF, Bertherat J, Chatellier G, Billaud E, Azizi M, Grouzmann E & Epelbaum J 1995 Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial. Clinical Endocrinology 42 289-294. (doi:10.1111/j.1365-2265.1995.tb01877.x)
49. Pupilli C, Lanzillotti R, Fiorelli G, Selli C, Gomez RA, Carey RM, Serio M & Mannelli M 1994 Dopamine D2 receptor gene expression and binding sites in adrenal medulla and pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 79 56-61. (doi:10.1210/jc.79.1.56)
50. Reubi JC & Laissue JA 1995 Multiple actions of somatostatin in neoplastic disease. Trends in Pharmacological Sciences 16 110-115. (doi:10.1016/S0165-6147(00)88992-0)
51. Reubi JC & Waser B 2003 Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 30 781-793. (doi:10.1007/s00259-003-1184-3)
52. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS & Macke HR 2000a Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. European Journal of Nuclear Medicine 27 273-282. (doi:10.1007/ s002590050034)
53. Reubi JC, Waser B, Liu Q, Laissue JA & Schonbrunn A 2000b Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. Journal of Clinical Endocrinology and Metabolism 85 3882-3891. (doi:10.1210/jc.85.10.3882)
54. Reubi JC, Waser B, Schaer JC & Laissue JA 2001 Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. European Journal of Nuclear Medicine 28 836-846. (doi:10.1007/s002590100541)
55. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A & Jaquet P 2001 Bim-23244 a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 86 140-145. (doi:10.1210/jc.86.1.140)
56. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A & Jaquet P 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. Journal of Clinical Endocrinology and Metabolism 87 5545-5552. (doi:10.1210/jc.2002-020934)
57. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD & Jaquet P 2006 Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83 258-263. (doi:10.1159/000095536)
58. Schmidt M, Fischer E, Dietlein M, Michel O, Weber K, Moka D, Stennert E & Schicha H 2002 Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. European Journal of Nuclear Medicine and Molecular Imaging 29 1571-1580. (doi:10.1007/s00259-002-0939-6)
59. Sharif N, Gendron L, Wowchuk J, Sarret P, Mazella J, Beaudet A & Stroh T 2007 Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 148 2095-2105. (doi:10.1210/en.2006-1266)
60. Srirangalingam U, Khoo B, Walker L, MacDonald F, Skelly RH, George E, Spooner D, Johnston LB, Monson JP, Grossman AB et al. 2009 Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocrine-Related Cancer 16 515-525. (doi:10.1677/ERC-08-0239)
61. 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clinical Endocrinology 69 580-586. (doi:10.1111/j.1365-2265.2008.03257.x)
62. Taieb D, Sebag F, Barlier A, Tessonnier L, Palazzo FF, Morange I, Niccoli-Sire P, Fakhry N, De Micco C, Cammilleri S et al. 2009 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? Journal of Nuclear Medicine 50 711-717. (doi:10.2967/jnumed.108.060731)
63. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B & Parmentier C 1995 Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. Journal of Nuclear Medicine 36 1-6.
64. Tonyukuk V, Emral R, Temizkan S, Sertcelik A, Erden I & Corapcioglu D 2003 Case report: patient with multiple paragangliomas treated with long acting somatostatin analogue. Endocrine Journal 50 507-513. (doi:10.1507/endocrj.50. 507)
65. Truong JG, Newman AH, Hanson GR & Fleckenstein AE 2004 Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. European Journal of Pharmacology 504 27-32. (doi:10.1016/j.ejphar.2004.09.049)
66. Ueberberg B, Tourne H, Redmann A, Walz MK, Schmid KW, Mann K & Petersenn S 2005 Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Hormone and Metabolic Research 37 722-728. (doi:10.1055/s-2005-921092)
67. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Schmid KW, Mann K & Petersenn S 2004 Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumors. Endocrine Research 30 931-934. (doi:10.1081/ERC-200044161)
68. Vaidyanathan G, Affleck DJ, Norman J, O'Dorisio S & Zalutsky MR 2007 A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells. Bioconjugate Chemistry 18 2122-2130. (doi:10.1021/bc700240r)
69. Van Essen M, Krenning EP, De Jong M, Valkema R & Kwekkeboom DJ 2007 Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica 46 723-734. (doi:10.1080/02841860701441848)
70. Weckbecker G, Briner U & Lewis I 2002 SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology 143 4123-4130. (doi:10.1210/en.2002-220219)
71. Wu KD, Chen YM, Chu TS, Chueh SC, Wu MH & Bor-Shen H 2001 Expression and localization of human dopamine D2 and D4 receptor mRNA in the adrenal gland, aldosterone-producing adenoma, and pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 86 4460-4467. (doi:10.1210/jc.86.9.4460)